{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:34:20Z","timestamp":1791646460026,"version":"4.3.4"},"reference-count":88,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhltonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Heart and Lung Transplantation"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.healun.2015.10.002","type":"journal-article","created":{"date-parts":[[2015,10,16]],"date-time":"2015-10-16T22:42:15Z","timestamp":1445035335000},"page":"151-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Anticoagulation in patients with pulmonary arterial hypertension: An update on current knowledge"],"prefix":"10.1016","volume":"35","author":[{"given":"Tamara","family":"Roldan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Landzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Deicicchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie K.","family":"Atay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron B.","family":"Waxman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25 Suppl","key":"10.1016\/j.healun.2015.10.002_bib1","doi-asserted-by":"crossref","first-page":"D51","DOI":"10.1016\/j.jacc.2013.10.023","article-title":"Pulmonary arterial hypertension: epidemiology and registries","volume":"62","author":"McGoon","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"25 Suppl","key":"10.1016\/j.healun.2015.10.002_bib2","doi-asserted-by":"crossref","first-page":"D34","DOI":"10.1016\/j.jacc.2013.10.029","article-title":"Updated clinical classification of pulmonary hypertension","volume":"62","author":"Simonneau","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2015.10.002_bib3","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMra040291","article-title":"Treatment of pulmonary arterial hypertension","volume":"351","author":"Humbert","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2015.10.002_bib4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s11739-009-0263-2","article-title":"Pulmonary arterial hypertension","volume":"4","author":"Wu","year":"2009","journal-title":"Intern Emerg Med"},{"issue":"1 Suppl","key":"10.1016\/j.healun.2015.10.002_bib5","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jacc.2009.04.018","article-title":"Cellular and molecular basis of pulmonary arterial hypertension","volume":"54","author":"Morrell","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2015.10.002_bib6","doi-asserted-by":"crossref","unstructured":"Galie N, Humbert M, Vachiery JL, et al. 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). [e-pub ahead of print]. Eur Heart J. Available at: http:\/\/dx.doi.org\/10.1093\/eurheartj\/ehv317. Accessed October 26, 2015.","DOI":"10.1093\/eurheartj\/ehv317"},{"key":"10.1016\/j.healun.2015.10.002_bib7","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jacc.2009.01.004","volume":"53","author":"McLaughlin","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"25 Suppl","key":"10.1016\/j.healun.2015.10.002_bib8","doi-asserted-by":"crossref","first-page":"D60","DOI":"10.1016\/j.jacc.2013.10.031","article-title":"Updated treatment algorithm of pulmonary arterial hypertension","volume":"62","author":"Galie","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2015.10.002_bib9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1378\/chest.14-0793","article-title":"Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report","volume":"146","author":"Taichman","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.healun.2015.10.002_bib10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.0954-6820.1966.tb05449.x","article-title":"Primary pulmonary hypertension with emphasis on its etiology and treatment","volume":"179","author":"Storstein","year":"1966","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.healun.2015.10.002_bib11","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.CIR.70.4.580","article-title":"Primary pulmonary hypertension: natural history and the importance of thrombosis","volume":"70","author":"Fuster","year":"1984","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2015.10.002_bib12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1164\/rccm.201209-1640OC","article-title":"Causes and circumstances of death in pulmonary arterial hypertension","volume":"188","author":"Tonelli","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.healun.2015.10.002_bib13","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0272-5231(05)70283-5","article-title":"Pathobiology of pulmonary hypertension. The role of platelets and thrombosis","volume":"22","author":"Herve","year":"2001","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.healun.2015.10.002_bib14","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1183\/09031936.98.12061446","article-title":"Plasma coagulation profiles in patients with severe primary pulmonary hypertension","volume":"12","author":"Hoeper","year":"1998","journal-title":"Eur Respir J"},{"key":"10.1016\/j.healun.2015.10.002_bib15","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0012-3692(15)51873-4","article-title":"Thrombotic arteriopathy and anticoagulation in pulmonary hypertension","volume":"130","author":"Johnson","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.healun.2015.10.002_bib16","first-page":"376","article-title":"Coagulation and anticoagulation in pulmonary arterial hypertension","volume":"11","author":"Berger","year":"2009","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.healun.2015.10.002_bib17","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1378\/chest.110.3.710","article-title":"Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension","volume":"110","author":"Welsh","year":"1996","journal-title":"Chest"},{"key":"10.1016\/j.healun.2015.10.002_bib18","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1161\/01.CIR.82.3.841","article-title":"Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension","volume":"82","author":"Eisenberg","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2015.10.002_bib19","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1183\/09031936.00039212","article-title":"Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension","volume":"41","author":"Henkens","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.healun.2015.10.002_bib20","first-page":"595","article-title":"Effect of warfarin anticoagulation on thrombin generation in patients with idiopathic pulmonary arterial hypertension","volume":"111","author":"Jansa","year":"2010","journal-title":"Bratisl Lek Listy"},{"key":"10.1016\/j.healun.2015.10.002_bib21","doi-asserted-by":"crossref","first-page":"R213","DOI":"10.1186\/ar4051","article-title":"Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study","volume":"14","author":"Ngian","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.healun.2015.10.002_bib22","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3899\/jrheum.100632","article-title":"Effect of warfarin on survival in scleroderma-associated pulmonary arterial hypertension (SSc-PAH) and idiopathic PAH. Belief elicitation for Bayesian priors","volume":"38","author":"Johnson","year":"2011","journal-title":"J Rheumatol"},{"issue":"25 Suppl","key":"10.1016\/j.healun.2015.10.002_bib23","doi-asserted-by":"crossref","first-page":"D92","DOI":"10.1016\/j.jacc.2013.10.024","article-title":"Chronic thromboembolic pulmonary hypertension","volume":"62","author":"Kim","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2015.10.002_bib24","first-page":"1196","article-title":"Results of one-year anticoagulation in patients with newly detected chronic thromboembolic pulmonary hypertension not treated with pulmonary endarterectomy","volume":"64","author":"Romaszkiewicz","year":"2006","journal-title":"Kardiol Pol"},{"key":"10.1016\/j.healun.2015.10.002_bib25","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","article-title":"The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension","volume":"327","author":"Rich","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2015.10.002_bib26","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1253\/jcj.57.63","article-title":"Effects of a combination therapy of anticoagulant and vasodilator on the long-term prognosis of primary pulmonary hypertension","volume":"57","author":"Ogata","year":"1993","journal-title":"Jpn Circ J"},{"key":"10.1016\/j.healun.2015.10.002_bib27","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1378\/chest.112.3.714","article-title":"The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension","volume":"112","author":"Frank","year":"1997","journal-title":"Chest"},{"key":"10.1016\/j.healun.2015.10.002_bib28","first-page":"761","article-title":"Clinico-hemodynamic study and treatment of 44 patients with primary pulmonary hypertension","volume":"118","author":"Roman","year":"2002"},{"key":"10.1016\/j.healun.2015.10.002_bib29","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.amjcard.2004.09.006","article-title":"New predictors of outcome in idiopathic pulmonary arterial hypertension","volume":"95","author":"Kawut","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.healun.2015.10.002_bib30","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1183\/09031936.06.00015206","article-title":"Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review","volume":"28","author":"Johnson","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.healun.2015.10.002_bib31","first-page":"A16034","article-title":"Effect of warfarin on long term pulmonary arterial hypertension (PAH) mortality: change of facts?","volume":"124","author":"Saeed","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2015.10.002_bib32","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3899\/jrheum.110765","article-title":"Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease","volume":"39","author":"Johnson","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.healun.2015.10.002_bib33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1161\/CIRCULATIONAHA.113.004526","article-title":"Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)","volume":"129","author":"Olsson","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2015.10.002_bib34","first-page":"A2464","article-title":"Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the registry to evaluate early and long-term PAH disease management (REVEAL)","volume":"189","author":"Preston","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.healun.2015.10.002_bib35","first-page":"6","article-title":"Anticoagulation therapy versus placebo for pulmonary hypertension","author":"Ezedunukwe","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.healun.2015.10.002_bib36","first-page":"879","article-title":"Oral anticoagulation for pulmonary arterial hypertension: systematic review and meta-analysis","volume":"30","author":"Caldeira","year":"2014","journal-title":"Can J Cardiol"},{"issue":"Suppl 1","key":"10.1016\/j.healun.2015.10.002_bib37","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.3949\/ccjm.70.Suppl_1.S18","article-title":"Treatments and strategies to optimize the comprehensive management of patients with pulmonary arterial hypertension","volume":"70","author":"Gildea","year":"2003","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.healun.2015.10.002_bib38","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2796.2005.01542.x","article-title":"Current treatment strategies for pulmonary arterial hypertension","volume":"258","author":"Lee","year":"2005","journal-title":"J Intern Med"},{"key":"10.1016\/j.healun.2015.10.002_bib39","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/j.ehj.2004.09.014","article-title":"Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology","volume":"25","author":"Galie","year":"2004","journal-title":"Eur Heart J"},{"issue":"1 Suppl","key":"10.1016\/j.healun.2015.10.002_bib40","doi-asserted-by":"crossref","first-page":"35S","DOI":"10.1378\/chest.126.1_suppl.35S","article-title":"Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines","volume":"126","author":"Badesch","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.healun.2015.10.002_bib41","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1161\/CIRCULATIONAHA.113.007666","article-title":"Letter by Suissa and Gali\u00e9 regarding article, \u201cAnticoagulation and survival in pulmonary arterial hypertension: results from the comparative, prospective registry of newly initiated therapies for pulmonary hypertension (COMPERA).\u201d","volume":"130","author":"Suissa","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2015.10.002_bib42","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1378\/chest.06-2674","article-title":"Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines","volume":"131","author":"Badesch","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.healun.2015.10.002_bib43","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/CIRCULATIONAHA.109.911818","article-title":"Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era","volume":"122","author":"Humbert","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2015.10.002_bib44","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1378\/chest.09-1140","article-title":"Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry","volume":"137","author":"Badesch","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.healun.2015.10.002_bib45","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/imj.12111","article-title":"Should patients with systemic sclerosis-related pulmonary arterial hypertension be anticoagulated?","volume":"43","author":"Nikpour","year":"2013","journal-title":"Intern Med J"},{"key":"10.1016\/j.healun.2015.10.002_bib46","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1183\/09031936.00056110","article-title":"Pulmonary arterial hypertension: a comparison between children and adults","volume":"37","author":"Barst","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.healun.2015.10.002_bib47","first-page":"206","article-title":"A new era in medical management of severe pediatric pulmonary arterial hypertension","volume":"26","author":"Ivy","year":"2010","journal-title":"Nihon Shoni Junkanki Gakkai Zasshi"},{"key":"10.1016\/j.healun.2015.10.002_bib48","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1747-0803.2012.00633.x","article-title":"Does anticoagulation in Eisenmenger syndrome impact long-term survival?","volume":"7","author":"Sandoval","year":"2012","journal-title":"Congenit Heart Dis"},{"key":"10.1016\/j.healun.2015.10.002_bib49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2009-09-241851","article-title":"The new oral anticoagulants","volume":"115","author":"Garcia","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.healun.2015.10.002_bib50","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/cvr\/cvr168","article-title":"A role for coagulation factor Xa in experimental pulmonary arterial hypertension","volume":"92","author":"Delbeck","year":"2011","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.healun.2015.10.002_bib51","unstructured":"ClinicalTrials.gov. Rivaroxaban in Thrombotic Antiphospholipid Syndrome (TRAPS). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02157272. Accessed December 17, 2014."},{"key":"10.1016\/j.healun.2015.10.002_bib52","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"Suppl 56","key":"10.1016\/j.healun.2015.10.002_bib53","first-page":"P1510","article-title":"Potential pharmacological interactions between oral pulmonary arterial hypertension (PAH) therapies and new oral anticoagulants","volume":"40","author":"Bertoletti","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.healun.2015.10.002_bib54","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.112.135681","article-title":"Bridging evidence-based practice and practice-based evidence in periprocedural anticoagulation","volume":"126","author":"Gallego","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2015.10.002_bib55","doi-asserted-by":"crossref","first-page":"e326S","DOI":"10.1378\/chest.11-2298","article-title":"Perioperative management of antithrombotic therapy. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Douketis","year":"2012","journal-title":"Chest"},{"issue":"2 Suppl","key":"10.1016\/j.healun.2015.10.002_bib56","doi-asserted-by":"crossref","first-page":"e691S","DOI":"10.1378\/chest.11-2300","article-title":"VTE, thrombophilia, antithrombotic therapy, and pregnancy. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Bates","year":"2012","journal-title":"Chest"},{"issue":"Suppl 2","key":"10.1016\/j.healun.2015.10.002_bib57","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1365-2362.2009.02122.x","article-title":"Bleeding events in pulmonary arterial hypertension","volume":"39","author":"Opitz","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.healun.2015.10.002_bib58","first-page":"1013","article-title":"Systemic sclerosis complicated by diffuse alveolar hemorrhage","volume":"7","author":"Chaer","year":"2001","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.healun.2015.10.002_bib59","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.semarthrit.2003.09.006","article-title":"Pulmonary hemorrhage in systemic lupus erythematosus","volume":"33","author":"Badsha","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.healun.2015.10.002_bib60","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2003.07.022","article-title":"Pulmonary thrombosis in adults with Eisenmenger syndrome","volume":"42","author":"Silversides","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2015.10.002_bib61","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.healun.2015.10.002_bib62","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11239-008-0219-9","article-title":"Warfarin: what are the clinical implications of an out-of-range-therapeutic international normalized ratio?","volume":"27","author":"Merli","year":"2009","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.healun.2015.10.002_bib63","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/hrt.2004.042465","article-title":"Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population","volume":"91","author":"Jones","year":"2005","journal-title":"Heart"},{"key":"10.1016\/j.healun.2015.10.002_bib64","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa022913","article-title":"Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation","volume":"349","author":"Hylek","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2015.10.002_bib65","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11239-006-4968-z","article-title":"Monitoring anticoagulation in atrial fibrillation","volume":"21","author":"Sarawate","year":"2006","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.healun.2015.10.002_bib66","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1378\/chest.127.5.1515","article-title":"Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy","volume":"127","author":"Witt","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.healun.2015.10.002_bib67","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1111\/j.1538-7836.2006.01997.x","article-title":"Early detection of patients with a poor response to vitamin K antagonists: the clinical impact of individual time within target range in patients with heart disease","volume":"4","author":"Veeger","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.healun.2015.10.002_bib68","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.thromres.2008.09.016","article-title":"Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control","volume":"124","author":"Morgan","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.healun.2015.10.002_bib69","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1160\/TH11-05-0353","article-title":"Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients","volume":"106","author":"Gallagher","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.healun.2015.10.002_bib70","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.thromres.2005.11.016","volume":"119","author":"Schmidt-Lucke","year":"2007","journal-title":"Thromb Res"},{"key":"10.1016\/j.healun.2015.10.002_bib71","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archinte.167.3.239","article-title":"Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V","volume":"167","author":"White","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.healun.2015.10.002_bib72","unstructured":"Flolan (epoprostenol sodium) for injection. Full prescribing information. Available at: http:\/\/us.gsk.com\/products\/assets\/us_flolan.pdf. Accessed March 27, 2014."},{"key":"10.1016\/j.healun.2015.10.002_bib73","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1161\/01.CIR.99.9.1197","article-title":"Vasodilator therapy for primary pulmonary hypertension in children","volume":"99","author":"Barst","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2015.10.002_bib74","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1253\/circj.69.216","article-title":"Risk of alveolar hemorrhage in patients with primary pulmonary hypertension\u2014anticoagulation and epoprostenol therapy","volume":"69","author":"Ogawa","year":"2005","journal-title":"Circ J"},{"key":"10.1016\/j.healun.2015.10.002_bib75","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.healun.2015.10.002_bib76","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s00246-013-0811-4","article-title":"Safety and tolerability of targeted therapies for pulmonary hypertension in children","volume":"35","author":"Roldan","year":"2014","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.healun.2015.10.002_bib77","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2015.10.002_bib78","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2015.10.002_bib79","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1177\/0091270010378119","article-title":"Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study","volume":"51","author":"Frey","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.healun.2015.10.002_bib80","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.112.000765","article-title":"Imatinib mesylate as add-on therapy for pulmonary arterial hypertension results of the randomized IMPRES study","volume":"127","author":"Hoeper","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2015.10.002_bib81","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1358\/dot.2013.49.3.1937430","article-title":"The role of imatinib in the treatment of pulmonary hypertension","volume":"49","author":"Mucke","year":"2013","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.healun.2015.10.002_bib82","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1016\/j.ijcard.2012.06.024","article-title":"Atrial flutter and fibrillation in patients with pulmonary hypertension","volume":"167","author":"Olsson","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.healun.2015.10.002_bib83","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1001\/jama.2014.15192","article-title":"Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized control trial","volume":"312","author":"Reddy","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.healun.2015.10.002_bib84","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3949\/ccjm.82a.14117","article-title":"Left atrial appendage closure: an emerging option in atrial fibrillation when oral anticoagulants are not tolerated","volume":"82","author":"Peritz","year":"2015","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.healun.2015.10.002_bib85","first-page":"e523","volume":"118","author":"Bonow","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2015.10.002_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.115.002028","article-title":"Left atrial appendage closure: killing 2 birds with 1 stone?","volume":"4","author":"Saba","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.healun.2015.10.002_bib87","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1183\/09031936.06.00095705","article-title":"A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension","volume":"27","author":"Robbins","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.healun.2015.10.002_bib88","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1161\/CIRCULATIONAHA.110.015693","article-title":"Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT","volume":"123","author":"Kawut","year":"2011","journal-title":"Circulation"}],"container-title":["The Journal of Heart and Lung Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249815014497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249815014497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T08:30:53Z","timestamp":1760949053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053249815014497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":88,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S1053249815014497"],"URL":"https:\/\/doi.org\/10.1016\/j.healun.2015.10.002","relation":{},"ISSN":["1053-2498"],"issn-type":[{"value":"1053-2498","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticoagulation in patients with pulmonary arterial hypertension: An update on current knowledge","name":"articletitle","label":"Article Title"},{"value":"The Journal of Heart and Lung Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healun.2015.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}